About Adial Pharmaceuticals
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.
The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder.
It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders.
The company was founded in 2010 and is based in Glen Allen, Virginia.